Navigation Links
KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants
Date:10/11/2007

ST. LOUIS, Oct. 11 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) announced today the results of the independent investigation by the Special Committee of the Board of Directors concerning historical stock option granting practices and related accounting.

On October 11, 2007, KV's Board of Directors unanimously accepted a final report on the previously submitted findings on the internal investigation of the Company's historical stock option grant practices. The investigation was conducted by a Special Committee of independent board members appointed by the Company's Board of Directors with the assistance of independent legal counsel and forensic accounting experts engaged by the Special Committee.

The investigation concluded that no employee, officer or director of the Company engaged in any intentional wrongdoing or was aware that the Company's policies and procedures for granting and accounting for stock options were materially non-compliant with U.S. Generally Accepted Accounting Principles (GAAP). The investigation also found no intentional violation of law or accounting rules with respect to the Company's historical stock option granting practices. Further, the Special Committee found that the Company's stock option granting and accounting practices, beginning April 2, 2006 are appropriate.

The Special Committee, however, concluded that certain compensation expenses resulting from the historical stock option granting practices followed by the Company during the period between 1996 and 2006 were not recorded in accordance with U.S. GAAP because they reflected incorrect measurement dates for financial accounting purposes. The option granting practices consistently followed under the Company's procedures for administering the Incentive Stock Option Plans (the plans) consisted of granting options based on the lowest price between the award date and the end of the quarter for existing employees and the first date of empl
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Setting up a new pharmaceutical industry in India
5. Medicis Pharmaceutical company enters pediatric market
6. Supply of Radiopharmaceuticals Hampered by Attacks
7. Pharmaceutical companies are targeting patients
8. FDA approves Watson Pharmaceuticals Oxytrol patch
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... FRANKLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstC...oice for medical intervention in treating 88 perce...50 percent of Americans treated for a chronic cond...rug spending and 75 percent of all medical costs. ...hree years by Medco Health Solutions, Inc. (NYSE: ...
(Date:11/21/2008)... Study found 2 popular drugs do not cause genetic...DAY, Nov. 21 (HealthDay News) -- Two popular medic...y disorder (ADHD) do not cause genetic damage link...ew study says. , The study, done by researchers...l Institutes of Health, counters a previous one th...
(Date:11/21/2008)... , In 430 B.C., a new and deadly diseaseits cause...eek city-state was teeming with citizens, soldiers...s and Sparta. As streets filled with corpses, soci...e illness returned twice and Athens lost a third o...of Athens marked the beginning of the end of the G...
(Date:11/21/2008)... NEW YORK, Nov. 21 /PRNewswire/ -- For the sec...our years , McCann Healthcare Worldwide,s agency ...ency network at the 22nd annual international RX C...wide agency offices won a total of 59 RX Club Awar...hese winning McCann Healthcare Worldwide agencies ...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
... have discovered a naturally occurring hormone tha...%. Mice lacking the gene for klotho began showing ...e and die after // about two months when compared ...is has indeed opened up new avenues into improving...
... report published in the latest edition of The Lan...n treating adults with malaria than the common dru...r the treatment // of severe malaria throughout Af... But even with prompt administration of the drug i...
...ug 26 . Japanese encephalitis deaths continue to r...ed 220 in less than a month. // Dr.T.N.Dhole from...i Post Graduate Institute of Medical Sciences bla... spread of the killer brain fever, which had been ...
...n country of Uganda reports that all the efforts t...ing. The report on this topic was reported in this...nosoma brucei rhodesiense sleeping // sickness in ...lt of the movement of the livestock reservoir of t...
Other Medicine News:Health News:Encephalitis Deaths Cross 220 in Uttar Pradesh 2
(Date:11/20/2008)...Newswire/ -- Radius Health ("Radius") announced to...o its second institutional financing round, increa...d the total amount raised since the company,s ince...l investors participated in the financing, led by ...pital, The Wellcome Trust, HealthCare Ventures, Ox...
(Date:11/19/2008)...9 Amgen,(Nasdaq: AMGN...subsidiary of,Takeda Pharmaceutical Company Limit...n the Phase 3 MONET1 trial evaluating motesanib (A...latin for the first-line treatment of,advanced no...ily suspended,following a planned safety data rev...
(Date:11/19/2008)...from Roche- , , MONTVALE, N.J., Nov. 19 /PR.... (Nasdaq: MEMY ) today announced that it has ac...f R3487/MEM 3454, its lead alpha-7 nicotinic recep...th schizophrenia (CIAS). The Company has randomiz... $5.0 million payment from its partner Roche. Mem...
(Date:11/18/2008)...008 Faces of Influenza survey underscores that mot...nza; Mother and Gold Medalist Kristi Yamaguchi joi...ewswire/ -- While 78 percent of mothers in the Uni...ally life-threatening disease that can strike anyo... get vaccinated this season, according to a new su...
Breaking Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Dense tissue promotes aggressive cancers 4581 1Dense tissue promotes aggressive cancers 4581 2Vermillion Announces Publication of Data Supporting Its Peripheral Artery Disease Diagnostic Test Program 25689 1Vermillion Announces Publication of Data Supporting Its Peripheral Artery Disease Diagnostic Test Program 25689 2Vermillion Announces Publication of Data Supporting Its Peripheral Artery Disease Diagnostic Test Program 25689 3RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked 3A Exclusive Wine Tasting Event To Benefit Fertile Hope 25687 1RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked 3A Exclusive Wine Tasting Event To Benefit Fertile Hope 25687 2The challenge of paying for quality nursing care 25685 1The challenge of paying for quality nursing care 25685 2
...nix Medical,Corporation (OTC BB: CONX) and the Com...l data demonstrating a significant correlation,bet...x(TM),bio-markers and cardiovascular disease. The ...ternational Society on Thrombosis and,Hemostasis (...week shows the association of antibodies to,the At...
... Portola,Pharmaceuticals, Inc. announced positive ...oral Factor Xa inhibitor, today at the XXI,Congres...aemostasis,(ISTH) in Geneva, Switzerland. The EXPE..., and well tolerated for the,prevention of venous ... total knee replacement (TKR) surgery. Portola exp...
Other Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 2Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 3Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis 4
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option.
300XL System, English (U.K. cord), 100-240 VAC.
Micro-mini fiber optic light.
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light.
Medicine Products: